Log in to your Inderes Free account to see all free content on this page.

Apotea

85.48 SEK

-0.88 %

Less than 1K followers

APOTEA

NASDAQ Stockholm

Personal Goods

Consumer Goods & Services

Overview

Financials & Estimates

Ownership

Investor consensus

-0.88 %

-1.13 %

-11.31 %

-9.95 %

+1.70 %

+1.76 %

-

-

+1.76 %

Apotea is active in the e-commerce sector. The company operates as an online pharmacy. The company sells and supplies a wide range of prescription and over-the-counter medicines, skin and hair care products as well as make-up and various beauty-related products. The company operates in the Swedish domestic market, where the customer base mainly consists of private individuals. Apotea was founded in 2003 and has its headquarters in Stockholm.

Market cap

9B SEK

Turnover

20.5M SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

4.2.

2026

Annual report '25

29.4.

2026

Interim report Q1'26

26.5.

2026

General meeting '26

All

Webcasts

Press releases

ShowingAll content types

Apotea, Webcast, Q3'25

Webcast11/6/2025, 8:30 AM

Apotea, Webcast, Q3'25

Regulatory press release11/6/2025, 6:30 AM

Apotea AB (publ) Interim report Q3 2025: Successful production launch in Varberg and continued good profitability

Press release10/3/2025, 8:00 AM

Invitation to Apotea’s Q3 2025 webcast

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release8/22/2025, 6:55 AM

Apotea: Employee representatives on the Board of Directors

Apotea, Webcast, Q2'25

Webcast7/18/2025, 7:30 AM

Apotea, Webcast, Q2'25

Regulatory press release7/18/2025, 5:30 AM

Apotea AB (publ) Interim report Q2 2025: Strengthened profitability and increased demand for prescription products

Press release6/18/2025, 6:30 AM

Invitation to Apotea's Q2 2025 webcast

Regulatory press release5/28/2025, 9:45 AM

Bulletin from Apotea AB's (publ) Annual General Meeting on May 28, 2025

Apotea, Webcast with teleconference, Q1'25

Webcast5/8/2025, 7:30 AM

Apotea, Webcast with teleconference, Q1'25

Regulatory press release5/8/2025, 5:30 AM

Apotea AB (publ) Interim report Q1 2025: Improved profitability and solid growth in times of uncertainty

Regulatory press release4/29/2025, 5:30 AM

Apotea publishes annual and sustainability report for the financial year 2024

Regulatory press release4/23/2025, 7:30 AM

Notice to Annual General Meeting in Apotea AB (publ)

Regulatory press release4/11/2025, 11:00 AM

The Nomination Committee's proposal for the Board of Directors of Apotea AB (publ)

Press release4/4/2025, 6:30 AM

Invitation to Apotea's Q1 2025 webcast

Regulatory press release4/3/2025, 7:30 PM

Apotea Sverige AB cooperates with the Swedish Competition Authority (Konkurrensverket) in an investigation on paid search advertising contacts

Apotea, Webcast, Q4'24

Webcast2/6/2025, 8:30 AM

Apotea, Webcast, Q4'24

Regulatory press release2/6/2025, 6:30 AM

Apotea AB (publ) Year-end report 2024: Strong growth and increased profitability

Press release1/13/2025, 9:00 AM

Invitation to Apotea's presentation of the year-end report 2024

Regulatory press release12/30/2024, 8:00 AM

Number of shares and votes in Apotea

Regulatory press release12/19/2024, 3:50 PM

Decision from IMY after inspection of Apotea AB (publ)

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.